Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson’s Disease Model
Table 5
Pharmacokinetic parameters of the NRG solution (i.v. and i.n.) and NE formulation after i.n. administration.
Formulation
Organ/Tissue
(ng/ml)
(h)
(H)
(ng/mlh)
(ng/mlh)
NRG sol (i.n.)
Brain
870.77 ± 5.4
2
6.84 ± 0.2
0.1 ± 0.003
3352.86 ± 8.9
5813.18 ± 9.2
Blood
775.44 ± 2.5
1
4.63 ± 0.4
0.14 ± 0.04
1919.734 ± 6.7
2554.17 ± 8.1
NRG NE (i.v.)
Brain
381.67 ± 3.1
1
7.44 ± 0. 8
0.09 ± 0.003
1599.36 ± 4.5
3118.87 ± 11.2
Blood
2502.74 ± 4.2
0.5
3.13 ± 0.7
0.22 ± 0.007
7533.91 ± 4.5
9582.21 ± 7.8
NRG NE (i.n.)
Brain
1148.64 ± 3.3
2
13.38 ± 1.1
0.05 ± 0.001
5345.13 ± 7.5
13543.23 ± 6.9
Blood
794.33 ± 7.1
2
10.4 ± 0.3
0.06 ± 0.02
3777.63 ± 5.3
8690.07 ± 8.5
Pharmacokinetic parameters results clearly indicated that the NRG concentration is significantly higher in optimized formulation administered via i.n. (p<0.05) than that of administration of optimized formulation via i.v. and NRG solution via i.v. route.